ICYMI: Continued biopharmaceutical action on COVID-19

This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry ’s response to COVID-19, caused by a novel strain of coronavirus. Daniel O’Day of Gilead Sciences, Julie Louise Gerberding, M.D., M.P.H. of Merck& Co., Inc, Paul Stoffels, M.D. of Johnson& Johnson, John Shiver, Ph.D. of Sanofi Pasteur and Steve Ubl of PhRMA were crucial contributors to the dialogue and offered updates and insights on their companies ’ and the industry's progress in the fight against the coronavirus.
Source: The Catalyst - Category: Pharmaceuticals Tags: PhRMA Member Company Vaccines Infectious Diseases Source Type: news